Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Hikma and Vectura to Produce Generic Versions of GSK’s Ellipta Meds

By Mike Botta | November 12, 2018

Hikma Pharmaceuticals and Vectura Group have signed an agreement for the global development and commercialization of generic versions of GlaxoSmithKline‘s Ellipta portfolio, using Vectura’s proprietary Open-Inhale-Close dry powder inhaler device.

The two companies believe the inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for the generic versions.

Net sales for Ellipta products in the U.S. are projected to be $4 billion by 2024 and approximately $5.5 billion globally, according to GlobalData (October 2018).

While the program includes the development of generics of up to five GSK respiratory medicines, Hikma and Vectura plan to  commercialize at least three of the products, with a generic version of Breo Ellipta (fluticasone furoate and vilanterol trifenatate) during the first wave.

Breo 100/25 is for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for reducing COPD exacerbations in patients with a history of exacerbations, according to GSK.

As part of the agreement, Hikma will make an upfront payment of $15 million to Vectura and Vectura will be responsible for, and fund, initial device and formulation development.

“The generic respiratory market is a key area of pipeline focus for Hikma,” Siggi Olafsson, chief executive officer of Hikma, said.  “This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus program. 

(Source: Hikma Pharmaceuticals PLC)

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards